Literature DB >> 34109629

Severe speech impairment is a distinguishing feature of FOXP1-related disorder.

Ruth O Braden1,2, David J Amor1,2,3,4, Simon E Fisher5,6, Cristina Mei1,7, Candace T Myers8, Heather Mefford8, Deepak Gill9, Siddharth Srivastava10, Lindsay C Swanson10, Himanshu Goel11, Ingrid E Scheffer1,2,3,12,13, Angela T Morgan1,2,3,4.   

Abstract

AIM: To delineate the speech and language phenotype of a cohort of individuals with FOXP1-related disorder.
METHOD: We administered a standardized test battery to examine speech and oral motor function, receptive and expressive language, non-verbal cognition, and adaptive behaviour. Clinical history and cognitive assessments were analysed together with speech and language findings.
RESULTS: Twenty-nine patients (17 females, 12 males; mean age 9y 6mo; median age 8y [range 2y 7mo-33y]; SD 6y 5mo) with pathogenic FOXP1 variants (14 truncating, three missense, three splice site, one in-frame deletion, eight cytogenic deletions; 28 out of 29 were de novo variants) were studied. All had atypical speech, with 21 being verbal and eight minimally verbal. All verbal patients had dysarthric and apraxic features, with phonological deficits in most (14 out of 16). Language scores were low overall. In the 21 individuals who carried truncating or splice site variants and small deletions, expressive abilities were relatively preserved compared with comprehension.
INTERPRETATION: FOXP1-related disorder is characterized by a complex speech and language phenotype with prominent dysarthria, broader motor planning and programming deficits, and linguistic-based phonological errors. Diagnosis of the speech phenotype associated with FOXP1-related dysfunction will inform early targeted therapy. What this paper adds Individuals with FOXP1-related disorder have a complex speech and language phenotype. Dysarthria, which impairs intelligibility, is the dominant feature of the speech profile. No participants were receiving speech therapy for dysarthria, but were good candidates for therapy Features of speech apraxia occur alongside persistent phonological errors. Language abilities are low overall; however, expressive language is a relative strength.
© 2021 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34109629     DOI: 10.1111/dmcn.14955

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  5 in total

1.  Genetic aetiologies for childhood speech disorder: novel pathways co-expressed during brain development.

Authors:  Antony Kaspi; Angela T Morgan; Michael S Hildebrand; Victoria E Jackson; Ruth Braden; Olivia van Reyk; Tegan Howell; Simone Debono; Mariana Lauretta; Lottie Morison; Matthew J Coleman; Richard Webster; David Coman; Himanshu Goel; Mathew Wallis; Gabriel Dabscheck; Lilian Downie; Emma K Baker; Bronwyn Parry-Fielder; Kirrie Ballard; Eva Harrold; Shaun Ziegenfusz; Mark F Bennett; Erandee Robertson; Longfei Wang; Amber Boys; Simon E Fisher; David J Amor; Ingrid E Scheffer; Melanie Bahlo
Journal:  Mol Psychiatry       Date:  2022-09-18       Impact factor: 13.437

Review 2.  Transcriptional Profile of the Developing Subthalamic Nucleus.

Authors:  Ema Bokulić; Tila Medenica; Goran Sedmak
Journal:  eNeuro       Date:  2022-10-18

3.  Social motivation a relative strength in DYRK1A syndrome on a background of significant speech and language impairments.

Authors:  Lottie D Morison; Ruth O Braden; David J Amor; Amanda Brignell; Bregje W M van Bon; Angela T Morgan
Journal:  Eur J Hum Genet       Date:  2022-04-18       Impact factor: 5.351

4.  Case report: FOXP1 syndrome caused by a de novo splicing variant (c.1652+5 G>A) of the FOXP1 gene.

Authors:  Min Chen; Yixi Sun; Yeqing Qian; Na Chen; Hongge Li; Liya Wang; Minyue Dong
Journal:  Front Genet       Date:  2022-08-05       Impact factor: 4.772

5.  Individuals with FOXP1 syndrome present with a complex neurobehavioral profile with high rates of ADHD, anxiety, repetitive behaviors, and sensory symptoms.

Authors:  M Pilar Trelles; Tess Levy; Bonnie Lerman; Paige Siper; Reymundo Lozano; Danielle Halpern; Hannah Walker; Jessica Zweifach; Yitzchak Frank; Jennifer Foss-Feig; Alexander Kolevzon; Joseph Buxbaum
Journal:  Mol Autism       Date:  2021-09-29       Impact factor: 7.509

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.